CCL

Összesen 11 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM067415
035-os BibID:(WoS)000392425200005 (Scopus)84991585385
Első szerző:Agca, R.
Cím:EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders : 2015/2016 update / R. Agca, S. C. Heslinga, S. Rollefstad, M. Heslinga, I. B. McInnes, M. J. L. Peters, T. K. Kvien, M. Dougados, H. Radner, F. Atzeni, J. Primdahl, A. Södergren, S. Wallberg Jonsson, J. van Rompay, C. Zabalan, T. R. Pedersen, L. Jacobsson, K. de Vlam, M. A. Gonzalez-Gay, A. G. Semb, G. D. Kitas, Y. M. Smulders, Z. Szekanecz, N. Sattar, D. P. M. Symmons, M. T. Nurmohamed
Dátum:2017
ISSN:0003-4967
Megjegyzések:Patients with rheumatoid arthritis (RA) and other inflammatory joint disorders (IJD) have increased cardiovascular disease (CVD) risk compared with the general population. In 2009, the European League Against Rheumatism (EULAR) taskforce recommended screening, identification of CVD risk factors and CVD risk management largely based on expert opinion. In view of substantial new evidence, an update was conducted with the aim of producing CVD risk management recommendations for patients with IJD that now incorporates an increasing evidence base. A multidisciplinary steering committee (representing 13 European countries) comprised 26 members including patient representatives, rheumatologists, cardiologists, internists, epidemiologists, a health professional and fellows. Systematic literature searches were performed and evidence was categorised according to standard guidelines. The evidence was discussed and summarised by the experts in the course of a consensus finding and voting process. Three overarching principles were defined. First, there is a higher risk for CVD in patients with RA, and this may also apply to ankylosing spondylitis and psoriatic arthritis. Second, the rheumatologist is responsible for CVD risk management in patients with IJD. Third, the use of non-steroidal anti-inflammatory drugs and corticosteroids should be in accordance with treatment-specific recommendations from EULAR and Assessment of Spondyloarthritis International Society. Ten recommendations were defined, of which one is new and six were changed compared with the 2009 recommendations. Each designated an appropriate evidence support level. The present update extends on the evidence that CVD risk in the whole spectrum of IJD is increased. This underscores the need for CVD risk management in these patients. These recommendations are defined to provide assistance in CVD risk management in IJD, based on expert opinion and scientific evidence.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:Annals Of The Rheumatic Diseases. - 76 : 1 (2017), p. 17-28. -
További szerzők:Heslinga, S. C. Rollefstad, S. Heslinga, M. McInnes, I. B. Peters, M. J. L. Kvien, Tore K. Dougados, Maxime Radner, H. Atzeni, F. Primdahl, Jette Södergren, A. Wallberg Jonsson, S. van Rompay, J. Zabalan, C. Pedersen, T. R. Jacobsson, L. de Vlam, K. Gonzalez-Gay, Miguel A. Semb, Anne Grete Kitas, George Smulders, Yvo M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Symmons, D. P. M. Nurmohamed, Michael T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM093358
035-os BibID:(WoS)000638059000001 (Scopus)85104071207
Első szerző:Atzeni, Fabiola
Cím:Cardiovascular effects of approved drugs for rheumatoid arthritis / Fabiola Atzeni, Javier Rodríguez-Carrio, Cǎlin D. Popa, Michael T. Nurmohamed, Gabriella Szűcs, Zoltán Szekanecz
Dátum:2021
ISSN:1759-4790 1759-4804
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Nature Reviews Rheumatology. - 17 : 5 (2021), p. 270-290. -
További szerzők:Rodríguez-Carrio, Javier Popa, Cǎlin D. Nurmohamed, Michael T. Szűcs Gabriella (1963-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM082647
Első szerző:Atzeni, Fabiola
Cím:Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs : a narrative review / Fabiola Atzeni, Valeria Nucera, James Galloway, Szekanecz Zoltán, Mike Nurmohamed
Dátum:2020
ISSN:1471-2598
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Expert Opinion On Biological Therapy. - 20 : 5 (2020), p. 517-524. -
További szerzők:Nucera, Valeria Galloway, James Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Nurmohamed, Michael T.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM056667
Első szerző:Choy, Ernest
Cím:Cardiovascular risk in rheumatoid arthritis : recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment / Ernest Choy, Kandeepan Ganeshalingam, Anne Grete Semb, Zoltán Szekanecz, Michael Nurmohamed
Dátum:2014
ISSN:1462-0324 1462-0332
Megjegyzések:Risk of cardiovascular (CV) disease is increased among RA patients. High inflammatory burden associated with RA appears to be a key driver of the increased cardiovascular risk. Inflammation is linked with accelerated atherosclerosis and associated with a paradoxical inversion of the relationship between CV risk and lipid levels in patients with untreated RA, recently coined the lipid paradox. Furthermore, the inflammatory burden is also associated with qualitative as well as quantitative changes in lipoproteins, with the anti-inflammatory and atheroprotective roles associated with high-density lipoprotein cholesterol significantly altered. RA therapies can increase lipid levels, which may reflect the normalization of lipids due to their inflammatory-dampening effects. However, these confounding influences of inflammation and RA therapies on lipid profiles pose challenges for assessing CV risk in RA patients and interpretation of traditional CV risk scores. In this review we examine the relationship between the increased inflammatory burden in RA and CV risk, exploring how inflammation influences lipid profiles, the impact of RA therapies and strategies for identifying and monitoring CV risk in RA patients aimed at improving CV outcomes.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
rheumatoid arthritis
cardiovascular disease
inflammation
atherosclerosis
dyslipidaemias
antirheumatic agents
Megjelenés:Rheumatology Oxford. - 53 : 12 (2014), p. 2143-2154. -
További szerzők:Ganeshalingam, Kandeepan Semb, Anne Grete Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Nurmohamed, Michael T.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Szerző által megadott URL
Borító:

5.

001-es BibID:BIBFORM051256
Első szerző:Damjanov, Nemanja
Cím:Biologics, cardiovascular effects and cancer / Nemanja Damjanov, Michael T. Nurmohamed, Zoltán Szekanecz
Dátum:2014
ISSN:1741-7015
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Megjelenés:BMC Medicine [electronic resource]. - 12 : 1 (2014), p. 48-50. -
További szerzők:Nurmohamed, Michael T. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:TÁMOP-4.2.4.A/2-11-1-2012-0001
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM100160
035-os BibID:(WOS)000750946900001 (Scopus)85125531096
Első szerző:Drosos, George C.
Cím:EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome / Drosos George C., Vedder Daisy, Houben Eline, Boekel Laura, Atzeni Fabiola, Badreh Sara, Boumpas Dimitrios T., Brodin Nina, Bruce Ian N., González-Gay Miguel Ángel, Jacobsen Sren, Kerekes György, Marchiori Francesca, Mukhtyar Chetan, Ramos-Casals Manuel, Sattar Naveed, Schreiber Karen, Sciascia Savino, Svenungsson Elisabet, Szekanecz Zoltan, Tausche Anne-Kathrin, Tyndall Alan, van Halm Vokko, Voskuyl Alexandre, Macfarlane Gary J., Ward Michael M., Nurmohamed Michael T., Tektonidou Maria G.
Dátum:2022
ISSN:0003-4967
Megjegyzések:Objective To develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). Methods Following European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion. Results Four overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or uratelowering therapy in gout has been associated with CVR lowering. Conclusion These recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Annals Of The Rheumatic Diseases. - 81 : 6 (2022), p. 768-779. -
További szerzők:Vedder, Daisy Houben, Eline Boekel, Laura Atzeni, Fabiola Badreh, Sara Boumpas, Dimitrios Brodin, Nina Bruce, Ian N. Gonzalez-Gay, Miguel A. Jacobsen, Sren Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Marchiori, Francesca Mukhtyar, Chetan Ramos-Casals, Manuel Sattar, Naveed Schreiber, Karen Sciascia, Savino Svenungsson, Elisabet Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Tausche, Anne-Kathrin Tyndall, Alan van Halm, Vokko Voskuyl, Alexandre Macfarlane, Gary J. Ward, Michael M. Nurmohamed, Michael T. Tektonidou, Maria G.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM054431
Első szerző:Kerekes György (belgyógyász, kardiológus, angiológus)
Cím:Rheumatoid arthritis and metabolic syndrome / György Kerekes, Michael T. Nurmohamed, Miguel A. González-Gay, Ildikó Seres, György Paragh, Zsófia Kardos, Zsuzsa Baráth, László Tamási, Pál Soltész, Zoltán Szekanecz
Dátum:2014
ISSN:1759-4790 1759-4804
Megjegyzések:Rheumatoid arthritis (RA), especially active disease, is associated with considerable changes in body composition, lipids, adipokines and insulin sensitivity. Metabolic changes, such as increased total cholesterol, LDL cholesterol and triglyceride levels, occur even in preclinical RA. Active RA is associated with decreased lipid levels, BMI, fat and muscle mass, as well as altered lipid profiles. Some of these changes are also seen in metabolic syndrome, and could increase cardiovascular mortality. Importantly, the systemic inflammation underlying RA is an independent risk factor for cardiovascular disease. This Perspectives article summarizes data on the associations of various components of metabolic syndrome with RA, and discusses the effects of biologic therapy on these factors. The authors propose that components of metabolic syndrome should be monitored in patients with RA throughout the disease course, and argue that optimal disease control using biologic agents might attenuate several adverse effects of metabolic syndrome in these patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
undifferentiated connetice tissue disease
entholtelial cell markers
endothelial dísfunction
flow-mediated vasodilation
accelered atherosclerosis
Megjelenés:Nature Reviews Rheumatology 10 : 11 (2014), p. 691-696. -
További szerzők:Nurmohamed, Michael T. Gonzalez-Gay, Miguel A. Seres Ildikó Paragh György (1953-) (belgyógyász) Kardos Zsófia Baráth Zsuzsa Tamási László Soltész Pál (1961-) (belgyógyász, kardiológus) Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0031
TÁMOP
TÁMOP-4.2.2.A-11/1/KONV-2012-0031
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM033405
Első szerző:Kerekes György (belgyógyász, kardiológus, angiológus)
Cím:Validated methods for assessment of subclinical atherosclerosis in rheumatology / György Kerekes, Pál Soltész, Michael T. Nurmohamed, Miguel A. Gonzalez-Gay, Maurizio Turiel, Edit Végh, Yehuda Shoenfeld, Iain McInnes, Zoltán Szekanecz
Dátum:2012
ISSN:1759-4790
Megjegyzések:Rheumatoid arthritis, as well as other types of arthritides and connective tissue diseases, is associated with accelerated atherosclerosis, and increased cardiovascular morbidity and mortality. The early signs of cardiovascular disease therefore need to be recognized in patients with these conditions so that effective cardiovascular protection can be introduced. This Review provides an overview of validated techniques that are currently available to determine subclinical atherosclerosis in patients with rheumatic conditions. Techniques for early assessment of endothelial dysfunction include brachial artery flow-mediated vasodilation and laser Doppler flowmetry. Coronary circulation can be assessed by measuring coronary flow reserve using CT, MRI or PET based techniques. The standard indicators of arterial stiffness are pulse-wave velocity and the augmentation index. Carotid atherosclerosis is determined by the common carotid intima- media thickness (ccIMT) measurement or by the assessment of plaques and plaque areas. The combination of ccIMT with plaque assessment is likely to increase the predictive value of this approach. The potential use of a multimarker approach to increase the diagnostic and prognostic value of these clinical assessments is also discussed.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
külföldön készült közlemény
Megjelenés:Nature Reviews Rheumatology 8 : 4 (2012), p. 224-234. -
További szerzők:Soltész Pál (1961-) (belgyógyász, kardiológus) Nurmohamed, Michael T. Gonzalez-Gay, Miguel A. Turiel, Maurizio Végh Edit (1978-) (reumatológus, belgyógyász) Shoenfeld, Yehuda McInnes, Iain Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Pályázati támogatás:TÁMOP-4.2.2.A-11/1/KONV-2012-0031
TÁMOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM075616
035-os BibID:(cikkazonosító)197
Első szerző:Nikiphorou, Elena (reumatológus)
Cím:Editorial : comorbidity burden in rheumatic diseases / Elena Nikiphorou, Michael T. Nurmohamed, Zoltan Szekanecz
Dátum:2018
ISSN:2296-858X
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
comorbidity
multimorbidity
rheumatic diseases
rheumatoid arthritis (RA)
treat-to-target
Megjelenés:Frontiers in Medicine. - 5 (2018), p. 1-3. -
További szerzők:Nurmohamed, Michael T. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus)
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM015844
Első szerző:Peters, M. J. L.
Cím:EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis / Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., Semb, A., Sidiropoulos, P., Kitas, G., Smulders, Y. M., Soubrier, M., Szekanecz, Z., Sattar, N., Nurmohamed, M. T.
Dátum:2010
ISSN:1468-2060 (Electronic)
Megjegyzések:To develop evidence-based EULAR recommendations for cardiovascular (CV) risk management in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA). METHODS: A multidisciplinary expert committee was convened as a task force of the EULAR Standing Committee for Clinical Affairs (ESCCA), comprising 18 members including rheumatologists, cardiologists, internists and epidemiologists, representing nine European countries. Problem areas and related keywords for systematic literature research were identified. A systematic literature research was performed using MedLine, Embase and the Cochrane library through to May 2008. Based on this literature review and in accordance with the EULAR's "standardised operating procedures", the multidisciplinary steering committee formulated evidence-based and expert opinion-based recommendations for CV risk screening and management in patients with inflammatory arthritis. RESULTS: Annual CV risk assessment using national guidelines is recommended for all patients with RA and should be considered for all patients with AS and PsA. Any CV risk factors identified should be managed according to local guidelines. If no local guidelines are available, CV risk management should be carried out according to the SCORE function. In addition to appropriate CV risk management, aggressive suppression of the inflammatory process is recommended to further lower the CV risk. CONCLUSIONS: Ten recommendations were made for CV risk management in patients with RA, AS and PsA. The strength of the recommendations differed between RA on the one hand, and AS and PsA, on the other, as evidence for an increased CV risk is most compelling for RA.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
Antihypertensive Agents/therapeutic use
Arthritis, Psoriatic/*complications
Arthritis, Rheumatoid/*complications
Cardiovascular Diseases/*etiology/*prevention & control
Cholesterol/blood
Drug Administration Schedule
Evidence-Based Medicine/methods
Female
Glucocorticoids/administration & dosage
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
Male
Risk Management/methods
Spondylitis, Ankylosing/*complications
Megjelenés:Annals of the Rheumatic Diseases. - 69 : 2 (2010), p. 325-331. -
További szerzők:Symmons, D. P. M. McCarey, D. Dijkmans, B. A. C. Nicola, P. Kvien, Tore K. McInnes, I. B. Haentzschel, H. Gonzalez-Gay, Miguel A. Provan, S. Semb, A. Sidiropoulos, P. Kitas, George Smulders, Yvo M. Soubrier, M. Szekanecz Zoltán (1964-) (reumatológus, belgyógyász, immunológus) Sattar, Naveed Nurmohamed, Michael T.
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
elektronikus változat
Borító:

11.

001-es BibID:BIBFORM044442
Első szerző:Szekanecz Zoltán (reumatológus, belgyógyász, immunológus)
Cím:Miscellaneous Inflammatory Arthritides 1 / Zoltán Szekanecz, György Kerekes, Michael Nurmohamed
Dátum:2012
Tárgyszavak:Orvostudományok Klinikai orvostudományok könyvfejezet
Megjelenés:Textbook on rheumatic diseases / eds. Johannes W. J. Bijlsma, Jose Antonia. - p. 390-420.
További szerzők:Kerekes György (1973-) (belgyógyász, kardiológus, angiológus) Nurmohamed, Michael T.
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1